You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 284 No. 12, September 27, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Brief Report
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on ISI (52)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Gastroenterology
 •Gastrointestinal Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Clinical Features and Treatment of Peristomal Pyoderma Gangrenosum

Amy P. Hughes, MD; J. Mark Jackson, MD; Jeffrey P. Callen, MD

JAMA. 2000;284:1546-1548.

Context  Peristomal pyoderma gangrenosum (PPG), an unusual variant of pyoderma gangrenosum, has been reported almost exclusively in patients with inflammatory bowel disease (IBD) and is frequently misdiagnosed.

Objective  To better characterize the clinical manifestations, diagnosis, and management of PPG.

Design, Setting, and Patients  Retrospective analysis of 7 patients with PPG observed in a university-affiliated community setting between 1988 and December 1999.

Main Outcome Measures  Clinical and histopathologic features, associated disorders, and microbiologic findings.

Results  Two patients had Crohn disease, 2 had ulcerative colitis, and 3 had abdominal cancer. Five patients had at least 1 relapse of PPG after initial healing. Although 3 of 4 patients with IBD had active bowel disease, a parallel course with PPG occurred in only 1 patient. Both patients whose stoma was relocated developed an ulcer at the new site. Effective therapies included topical superpotent corticosteroids; intralesional injection of triamcinolone acetonide at the ulcer margin; topical cromolyn sodium; oral dapsone, prednisone, cyclosporine, mycophenolate mofetil; and intravenous infliximab.

Conclusion  Our experiences demonstrate that although PPG has been most often reported in patients with IBD, it may occur in the absence of IBD. Biopsy of the skin lesion is not diagnostic but excludes other causes. Relocation of the stoma may be associated with a new ulceration and should be avoided. Trauma to the skin of a predisposed patient may elicit the pustules or ulcerations associated with pathergy.


Author Affiliations: Division of Dermatology, Department of Medicine, University of Louisville School of Medicine, Louisville, Ky.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED ARTICLE

September 27, 2000
JAMA. 2000;284(12):1587-1588.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Diagnosis and treatment of pyoderma gangrenosum
Brooklyn et al.
BMJ 2006;333:181-184.
FULL TEXT  

Important cutaneous manifestations of inflammatory bowel disease
Trost and McDonnell
Postgrad. Med. J. 2005;81:580-585.
ABSTRACT | FULL TEXT  

Mycophenolate Mofetil Is an Effective Treatment for Peristomal Pyoderma Gangrenosum
Daniels and Callen
Arch Dermatol 2004;140:1427-1429.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.